Supplementary Table 1.docx (55.33 kB)
Download fileSupplementary Table 1. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies
figure
posted on 2021-06-22, 08:28 authored by Nina Shah, Miguel-Angel Perales, Cameron J Turtle, Mitchell S Cairo, Andrew J Cowan, Hayder Saeed, Lihua E Budde, Alan Tan, Zachary Lee, Kazuharu Kai, Mario Q Marcondes, Jonathan Zalevsky, Mary A Tagliaferri, Krina K PatelSupplementary Box 1. Eligibility criteria for a Phase 1 study of NKTR-255 as monotherapy, or in combination with daratumumab or rituximab, in hematologic malignancies
